UNIGE document Scientific Article
previous document  unige:31436  next document
add to browser collection
Title

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

Authors
Corbacioglu, Selim
Cesaro, Simone
Faraci, Maura
Valteau-Couanet, Dominique
Gruhn, Bernd
Rovelli, Attilio
Boelens, Jaap J
Hewitt, Annette
show hidden authors show all authors [1 - 36]
Published in The Lancet. 2012, vol. 379, no. 9823, p. 1301-9
Abstract Hepatic veno-occlusive disease is a leading cause of morbidity and mortality after haemopoietic stem-cell transplantation (HSCT). We aimed to assess whether defibrotide can reduce the incidence of veno-occlusive disease in this setting.
Keywords AdolescentBilirubin/bloodChildChild, PreschoolFemaleFibrinolytic Agents/therapeutic useGraft vs Host Disease/epidemiologyHematopoietic Stem Cell Transplantation/adverse effectsHepatic Veno-Occlusive Disease/drug therapy/epidemiology/prevention & controlHumansIncidenceInfantInfusions, IntravenousMaleMultiple Organ Failure/epidemiologyPolydeoxyribonucleotides/therapeutic useRenal Insufficiency/epidemiology
Identifiers
PMID: 22364685
Full text
Article (Published version) (210 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Groupe Ozsahin Ayse Hulya (onco-hémato pédiatrie) (889)
Citation
(ISO format)
CORBACIOGLU, Selim et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. In: The Lancet, 2012, vol. 379, n° 9823, p. 1301-9. https://archive-ouverte.unige.ch/unige:31436

164 hits

0 download

Update

Deposited on : 2013-11-27

Export document
Format :
Citation style :